15% OFF $150+· CodeFALL15
Ends October 15Shop now
Lot certificates published
Plain, secure packaging
Purely Peptides
Research Catalog

same family

Survodutide vs Mazdutide

Survodutide and mazdutide are distinct peptide analogs with different main-chain sequences, conjugation positions, linkers and lipids.

Published: 2026-10-03Library record comparison: 2026-10-03

01

Identity side by side

Recorded molecular identities of Survodutide and Mazdutide
Recorded fieldSurvodutideMazdutide
Canonical nameSurvodutideMazdutide
AliasesBI 456906; BI-456906IBI362; IBI-362; LY3305677; LY-3305677
Development codesBI 456906IBI362; LY3305677
CAS2805997-46-82259884-03-0
UNII2ALA66NS64MB76Z4IBZ5
PubChem CID171378821not recorded
Molecular formulaC192H289N47O61C210H322N46O67
Molecular weight (Da)4231.634563.07
Sequence length (residues)2934
Terminal modificationsFree N-terminus; C-terminal amide at Ala29Free N-terminus; C-terminal amide at Gly34
Structural modificationsAc4c at position 2; Lys24 side-chain branched linker; C18 dicarboxylic fatty-acid acylationAib at position 2; Lys20 acylation via two AEEA spacers and gamma-Glu; C20 dicarboxylic fatty-acid acylation

Survodutide: nomenclature notes

A registry representation showing the main chain and the linker as separate sequences does not mean the substance is a mixture of two peptides. Survodutide and mazdutide are both GLP-1/glucagon dual agonists and are not interchangeable: they differ in main-chain sequence, nonstandard residue, conjugation position, linker and lipid. Shared receptor pharmacology is a classification, not chemical equivalence.

Mazdutide: nomenclature notes

The formula recorded here is the WHO-defined structure. PubChem's name-linked record reports C207H317N45O65, which differs by exactly one serine residue — C3H5NO2, 87.0320 Da. That is a difference in covalent peptide composition, not a salt form or a protonation state. This library anchors identity to the WHO 34-residue structure ending GGPSSG-NH2 and records no PubChem CID until the disagreement is reconciled upstream. The discrepancy is evidence of a database conflict; it is not evidence about what any particular sample contains.

02

Recorded modification details

An aligned one-letter sequence is not recorded for this pair. The stored modification and sequence notes are shown below.

Survodutide

Terminal modifications
Free N-terminus; C-terminal amide at Ala29
Structural modifications
Ac4c at position 2; Lys24 side-chain branched linker; C18 dicarboxylic fatty-acid acylation
Stored three-letter notation
His · Ac4c · Gln · Gly · Thr · Phe · Thr · Ser · Asp · Tyr · Ser · Lys · Tyr · Leu · Asp · Glu · Arg · Ala · Ala · Lys · Asp · Phe · Ile · Lys · Trp · Leu · Glu · Ser · Ala · NH2
Sequence notes
Position 2 is Ac4c, 1-aminocyclobutane-1-carboxylic acid. It is NOT Aib. The two differ by one carbon, 12.0000 Da exactly, and substituting one for the other imports the chemistry of a different peptide. The 29-residue main chain is also not the whole molecule: a gamma-Glu-Gly-Ser-Gly-Ser-Gly-Gly linker is amidated to the Lys24 side chain and carries a C18 dicarboxylic fatty acid.

Mazdutide

Terminal modifications
Free N-terminus; C-terminal amide at Gly34
Structural modifications
Aib at position 2; Lys20 acylation via two AEEA spacers and gamma-Glu; C20 dicarboxylic fatty-acid acylation
Stored three-letter notation
His · Aib · Gln · Gly · Thr · Phe · Thr · Ser · Asp · Tyr · Ser · Lys · Tyr · Leu · Asp · Glu · Lys · Lys · Ala · Lys · Glu · Phe · Val · Glu · Trp · Leu · Leu · Glu · Gly · Gly · Pro · Ser · Ser · Gly · NH2
Sequence notes
Thirty-four residues ending Gly-Gly-Pro-Ser-Ser-Gly with a C-terminal amide. BOTH serines near the C-terminus belong in the sequence; a species missing one would be 87.0320 Da lighter. Position 2 is Aib, 2-aminoisobutyric acid — not Ac4c, which is what survodutide carries. Lys20 is acylated through two AEEA spacers, a gamma-L-glutamyl unit and a C20 dicarboxylic fatty acid.

03

Recorded mechanisms

These lists show the links recorded in each monograph. An unlisted link does not establish its absence from the molecule’s biology.

Recorded only for Survodutide

not recorded

Recorded only for Mazdutide

not recorded

04

Recorded compound classes

Shared recorded links

Recorded only for Survodutide

not recorded

Recorded only for Mazdutide

not recorded

05

References for the relationship

  1. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.

    Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ, Klein H, Santhanam R, Hamprecht D, Neubauer H, Augustin R

    Molecular metabolism · 2022-11-07 · Journal Article

    current
    PMID 36356832PMC9679702DOI 10.1016/j.molmet.2022.101633SurvodutideGlucagonGLP-1RGCGR
  2. Structural analysis of the dual agonism at GLP-1R and GCGR.

    Li Y, Zhou Q, Dai A, Zhao F, Chang R, Ying T, Wu B, Yang D, Wang MW, Cong Z

    Proceedings of the National Academy of Sciences of the United States of America · 2023-08-07 · Journal Article

    current
    PMID 37549266PMC10438375DOI 10.1073/pnas.2303696120SurvodutideMazdutideGLP-1RGCGR

06

Read the full monographs

Survodutide →Mazdutide →